Immunotherapy before lung cancer surgery for stage 3 disease
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help shrink stage 3 lung cancer and improve outcomes. The goal is to make the tumor easier to remove and possibly lower the chance of it coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage 3 non-small cell lung cancer (the most common type) that has spread to certain lymph nodes or has other high-risk features.
- Your tumor can be removed with surgery, and you are healthy enough for the operation.
- Your cancer has not spread to distant organs (stage 4).
- With one exception, you have not had prior chemotherapy or immunotherapy for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
This study tests a combination of an immunotherapy drug (sintilimab) and chemotherapy to see if it can shrink advanced lung cancer enough to make surgery possible. The goal is to improve outcomes for people whose cancer is currently too extensive for surgery.
This trial tests a drug called cemiplimab, which helps your immune system fight cancer. It is given before and after surgery to try to reduce the chance of the cancer coming back.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
This trial tests whether giving the drug cemiplimab before surgery can help treat early-stage non-small cell lung cancer. The goal is to see if it shrinks the tumor or improves outcomes when followed by standard surgery.
This trial tests a new combination of drugs given before surgery for stage III lung cancer. It aims to shrink the tumor to make surgery more effective and possibly improve your chances of a cure.
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.